nodes	percent_of_prediction	percent_of_DWPC	metapath
Levocabastine—Eyelid oedema—Imiquimod—skin cancer	0.0499	0.0743	CcSEcCtD
Levocabastine—NTSR2—Peptide GPCRs—MC1R—skin cancer	0.0377	0.149	CbGpPWpGaD
Levocabastine—Stinging—Imiquimod—skin cancer	0.0311	0.0463	CcSEcCtD
Levocabastine—HRH1—nose—skin cancer	0.0309	0.411	CbGeAlD
Levocabastine—Lacrimation—Fluorouracil—skin cancer	0.0236	0.0352	CcSEcCtD
Levocabastine—NTSR2—head—skin cancer	0.0233	0.309	CbGeAlD
Levocabastine—NTSR2—Peptide ligand-binding receptors—MC1R—skin cancer	0.0177	0.07	CbGpPWpGaD
Levocabastine—Stinging—Fluorouracil—skin cancer	0.0172	0.0255	CcSEcCtD
Levocabastine—Lacrimation—Docetaxel—skin cancer	0.0171	0.0254	CcSEcCtD
Levocabastine—Lacrimation increased—Fluorouracil—skin cancer	0.0151	0.0225	CcSEcCtD
Levocabastine—Fatigue—Vismodegib—skin cancer	0.0147	0.0219	CcSEcCtD
Levocabastine—Pain—Vismodegib—skin cancer	0.0146	0.0217	CcSEcCtD
Levocabastine—NTSR2—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.0139	0.0548	CbGpPWpGaD
Levocabastine—Erythema—Vemurafenib—skin cancer	0.0129	0.0192	CcSEcCtD
Levocabastine—Pharyngitis—Imiquimod—skin cancer	0.0125	0.0187	CcSEcCtD
Levocabastine—NTSR2—GPCR ligand binding—PTCH2—skin cancer	0.0125	0.0494	CbGpPWpGaD
Levocabastine—Asthenia—Vismodegib—skin cancer	0.0122	0.0182	CcSEcCtD
Levocabastine—Visual impairment—Imiquimod—skin cancer	0.0122	0.0181	CcSEcCtD
Levocabastine—Eye pain—Temozolomide—skin cancer	0.0121	0.0181	CcSEcCtD
Levocabastine—NTSR2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.0119	0.0469	CbGpPWpGaD
Levocabastine—Cough—Vemurafenib—skin cancer	0.0113	0.0168	CcSEcCtD
Levocabastine—Erythema—Imiquimod—skin cancer	0.011	0.0164	CcSEcCtD
Levocabastine—Lacrimation increased—Docetaxel—skin cancer	0.0109	0.0162	CcSEcCtD
Levocabastine—Rash—Vismodegib—skin cancer	0.0107	0.016	CcSEcCtD
Levocabastine—Dermatitis—Vismodegib—skin cancer	0.0107	0.016	CcSEcCtD
Levocabastine—Nausea—Vismodegib—skin cancer	0.0101	0.0151	CcSEcCtD
Levocabastine—Cough—Imiquimod—skin cancer	0.0096	0.0143	CcSEcCtD
Levocabastine—Dry mouth—Imiquimod—skin cancer	0.00916	0.0136	CcSEcCtD
Levocabastine—NTSR2—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00912	0.036	CbGpPWpGaD
Levocabastine—Fatigue—Vemurafenib—skin cancer	0.00908	0.0135	CcSEcCtD
Levocabastine—NTSR2—GPCR ligand binding—MC1R—skin cancer	0.00905	0.0357	CbGpPWpGaD
Levocabastine—Pharyngitis—Dactinomycin—skin cancer	0.00831	0.0124	CcSEcCtD
Levocabastine—Dyspnoea—Imiquimod—skin cancer	0.00801	0.0119	CcSEcCtD
Levocabastine—Somnolence—Imiquimod—skin cancer	0.00798	0.0119	CcSEcCtD
Levocabastine—Erythema—Bleomycin—skin cancer	0.00782	0.0116	CcSEcCtD
Levocabastine—NTSR2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00781	0.0309	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—RHOU—skin cancer	0.00777	0.0307	CbGpPWpGaD
Levocabastine—Fatigue—Imiquimod—skin cancer	0.00774	0.0115	CcSEcCtD
Levocabastine—Visual disturbance—Docetaxel—skin cancer	0.00769	0.0114	CcSEcCtD
Levocabastine—Pain—Imiquimod—skin cancer	0.00768	0.0114	CcSEcCtD
Levocabastine—Asthenia—Vemurafenib—skin cancer	0.00756	0.0113	CcSEcCtD
Levocabastine—Pharyngitis—Temozolomide—skin cancer	0.00752	0.0112	CcSEcCtD
Levocabastine—Visual impairment—Temozolomide—skin cancer	0.0073	0.0109	CcSEcCtD
Levocabastine—Erythema—Dactinomycin—skin cancer	0.00729	0.0109	CcSEcCtD
Levocabastine—Pharyngitis—Fluorouracil—skin cancer	0.00693	0.0103	CcSEcCtD
Levocabastine—Cough—Bleomycin—skin cancer	0.00682	0.0102	CcSEcCtD
Levocabastine—Rash—Vemurafenib—skin cancer	0.00664	0.00989	CcSEcCtD
Levocabastine—Dermatitis—Vemurafenib—skin cancer	0.00663	0.00988	CcSEcCtD
Levocabastine—Headache—Vemurafenib—skin cancer	0.0066	0.00982	CcSEcCtD
Levocabastine—Erythema—Temozolomide—skin cancer	0.0066	0.00982	CcSEcCtD
Levocabastine—NTSR2—GPCR ligand binding—SHH—skin cancer	0.00645	0.0255	CbGpPWpGaD
Levocabastine—Asthenia—Imiquimod—skin cancer	0.00644	0.00959	CcSEcCtD
Levocabastine—NTSR2—Signaling by GPCR—PTCH2—skin cancer	0.00642	0.0254	CbGpPWpGaD
Levocabastine—Nausea—Vemurafenib—skin cancer	0.00626	0.00931	CcSEcCtD
Levocabastine—NTSR2—GPCR ligand binding—PTCH1—skin cancer	0.00611	0.0241	CbGpPWpGaD
Levocabastine—NTSR2—GPCR ligand binding—SMO—skin cancer	0.00611	0.0241	CbGpPWpGaD
Levocabastine—Erythema—Fluorouracil—skin cancer	0.00608	0.00905	CcSEcCtD
Levocabastine—NTSR2—GPCR ligand binding—PTGER4—skin cancer	0.00595	0.0235	CbGpPWpGaD
Levocabastine—Cough—Temozolomide—skin cancer	0.00575	0.00857	CcSEcCtD
Levocabastine—Dyspnoea—Bleomycin—skin cancer	0.00569	0.00847	CcSEcCtD
Levocabastine—Rash—Imiquimod—skin cancer	0.00566	0.00843	CcSEcCtD
Levocabastine—Dermatitis—Imiquimod—skin cancer	0.00566	0.00842	CcSEcCtD
Levocabastine—Headache—Imiquimod—skin cancer	0.00563	0.00838	CcSEcCtD
Levocabastine—Dry mouth—Temozolomide—skin cancer	0.00549	0.00818	CcSEcCtD
Levocabastine—Pain—Bleomycin—skin cancer	0.00546	0.00812	CcSEcCtD
Levocabastine—Nausea—Imiquimod—skin cancer	0.00533	0.00794	CcSEcCtD
Levocabastine—Fatigue—Dactinomycin—skin cancer	0.00513	0.00764	CcSEcCtD
Levocabastine—NTSR2—GPCR downstream signaling—MC1R—skin cancer	0.00511	0.0202	CbGpPWpGaD
Levocabastine—Pain—Dactinomycin—skin cancer	0.00509	0.00758	CcSEcCtD
Levocabastine—HRH1—nipple—skin cancer	0.00503	0.0669	CbGeAlD
Levocabastine—Pharyngitis—Docetaxel—skin cancer	0.005	0.00745	CcSEcCtD
Levocabastine—Visual impairment—Docetaxel—skin cancer	0.00486	0.00723	CcSEcCtD
Levocabastine—Dyspnoea—Temozolomide—skin cancer	0.0048	0.00714	CcSEcCtD
Levocabastine—Somnolence—Temozolomide—skin cancer	0.00479	0.00712	CcSEcCtD
Levocabastine—NTSR2—Signaling by GPCR—MC1R—skin cancer	0.00464	0.0183	CbGpPWpGaD
Levocabastine—Fatigue—Temozolomide—skin cancer	0.00464	0.00691	CcSEcCtD
Levocabastine—Pain—Temozolomide—skin cancer	0.0046	0.00685	CcSEcCtD
Levocabastine—Asthenia—Bleomycin—skin cancer	0.00458	0.00682	CcSEcCtD
Levocabastine—Dyspnoea—Fluorouracil—skin cancer	0.00442	0.00658	CcSEcCtD
Levocabastine—Somnolence—Fluorouracil—skin cancer	0.00441	0.00656	CcSEcCtD
Levocabastine—Erythema—Docetaxel—skin cancer	0.00439	0.00653	CcSEcCtD
Levocabastine—Asthenia—Dactinomycin—skin cancer	0.00427	0.00636	CcSEcCtD
Levocabastine—Pain—Fluorouracil—skin cancer	0.00424	0.00631	CcSEcCtD
Levocabastine—Rash—Bleomycin—skin cancer	0.00402	0.00599	CcSEcCtD
Levocabastine—Dermatitis—Bleomycin—skin cancer	0.00402	0.00598	CcSEcCtD
Levocabastine—Asthenia—Temozolomide—skin cancer	0.00386	0.00575	CcSEcCtD
Levocabastine—Cough—Docetaxel—skin cancer	0.00383	0.0057	CcSEcCtD
Levocabastine—NTSR2—Signaling Pathways—PTCH2—skin cancer	0.00379	0.015	CbGpPWpGaD
Levocabastine—Nausea—Bleomycin—skin cancer	0.00379	0.00564	CcSEcCtD
Levocabastine—Rash—Dactinomycin—skin cancer	0.00375	0.00559	CcSEcCtD
Levocabastine—Dry mouth—Docetaxel—skin cancer	0.00365	0.00544	CcSEcCtD
Levocabastine—HRH1—connective tissue—skin cancer	0.00357	0.0474	CbGeAlD
Levocabastine—Nausea—Dactinomycin—skin cancer	0.00353	0.00526	CcSEcCtD
Levocabastine—Rash—Temozolomide—skin cancer	0.00339	0.00505	CcSEcCtD
Levocabastine—Dermatitis—Temozolomide—skin cancer	0.00339	0.00505	CcSEcCtD
Levocabastine—HRH1—epithelium—skin cancer	0.00339	0.045	CbGeAlD
Levocabastine—Headache—Temozolomide—skin cancer	0.00337	0.00502	CcSEcCtD
Levocabastine—NTSR2—GPCR downstream signaling—PTGER4—skin cancer	0.00336	0.0133	CbGpPWpGaD
Levocabastine—NTSR2—Signaling by GPCR—SHH—skin cancer	0.00331	0.0131	CbGpPWpGaD
Levocabastine—Nausea—Temozolomide—skin cancer	0.0032	0.00476	CcSEcCtD
Levocabastine—Dyspnoea—Docetaxel—skin cancer	0.00319	0.00475	CcSEcCtD
Levocabastine—Somnolence—Docetaxel—skin cancer	0.00318	0.00474	CcSEcCtD
Levocabastine—NTSR2—Signaling by GPCR—SMO—skin cancer	0.00314	0.0124	CbGpPWpGaD
Levocabastine—NTSR2—Signaling by GPCR—PTCH1—skin cancer	0.00314	0.0124	CbGpPWpGaD
Levocabastine—Rash—Fluorouracil—skin cancer	0.00313	0.00466	CcSEcCtD
Levocabastine—Dermatitis—Fluorouracil—skin cancer	0.00312	0.00465	CcSEcCtD
Levocabastine—Headache—Fluorouracil—skin cancer	0.00311	0.00463	CcSEcCtD
Levocabastine—NTSR2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.0031	0.0122	CbGpPWpGaD
Levocabastine—Fatigue—Docetaxel—skin cancer	0.00309	0.00459	CcSEcCtD
Levocabastine—Pain—Docetaxel—skin cancer	0.00306	0.00456	CcSEcCtD
Levocabastine—NTSR2—Signaling by GPCR—PTGER4—skin cancer	0.00305	0.0121	CbGpPWpGaD
Levocabastine—Nausea—Fluorouracil—skin cancer	0.00295	0.00439	CcSEcCtD
Levocabastine—HRH1—mammalian vulva—skin cancer	0.00294	0.0391	CbGeAlD
Levocabastine—NTSR2—Signaling Pathways—GLI2—skin cancer	0.00288	0.0114	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—MC1R—skin cancer	0.00274	0.0108	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—GLI1—skin cancer	0.0027	0.0107	CbGpPWpGaD
Levocabastine—NTSR2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.00267	0.0105	CbGpPWpGaD
Levocabastine—Asthenia—Docetaxel—skin cancer	0.00257	0.00382	CcSEcCtD
Levocabastine—NTSR2—Signaling Pathways—SUFU—skin cancer	0.00256	0.0101	CbGpPWpGaD
Levocabastine—HRH1—female reproductive system—skin cancer	0.00252	0.0335	CbGeAlD
Levocabastine—NTSR2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.00227	0.00895	CbGpPWpGaD
Levocabastine—Rash—Docetaxel—skin cancer	0.00226	0.00336	CcSEcCtD
Levocabastine—Dermatitis—Docetaxel—skin cancer	0.00225	0.00336	CcSEcCtD
Levocabastine—Headache—Docetaxel—skin cancer	0.00224	0.00334	CcSEcCtD
Levocabastine—NTSR2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.00217	0.00857	CbGpPWpGaD
Levocabastine—Nausea—Docetaxel—skin cancer	0.00213	0.00317	CcSEcCtD
Levocabastine—HRH1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.0021	0.00831	CbGpPWpGaD
Levocabastine—HRH1—head—skin cancer	0.0021	0.028	CbGeAlD
Levocabastine—NTSR2—Signaling Pathways—SHH—skin cancer	0.00195	0.00772	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—RASA1—skin cancer	0.00194	0.00767	CbGpPWpGaD
Levocabastine—HRH1—GPCR ligand binding—PTCH2—skin cancer	0.0019	0.0075	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—PTCH1—skin cancer	0.00185	0.00732	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—SMO—skin cancer	0.00185	0.00732	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—PTGER4—skin cancer	0.0018	0.00713	CbGpPWpGaD
Levocabastine—HRH1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.0018	0.00712	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—FOXO4—skin cancer	0.00159	0.00629	CbGpPWpGaD
Levocabastine—HRH1—lymph node—skin cancer	0.00147	0.0196	CbGeAlD
Levocabastine—HRH1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00138	0.00546	CbGpPWpGaD
Levocabastine—HRH1—GPCR ligand binding—MC1R—skin cancer	0.00137	0.00542	CbGpPWpGaD
Levocabastine—HRH1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00119	0.00468	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—RHOU—skin cancer	0.00118	0.00466	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—TERT—skin cancer	0.00106	0.0042	CbGpPWpGaD
Levocabastine—HRH1—GPCR ligand binding—SHH—skin cancer	0.000978	0.00386	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—PTCH2—skin cancer	0.000974	0.00385	CbGpPWpGaD
Levocabastine—HRH1—GPCR ligand binding—SMO—skin cancer	0.000927	0.00366	CbGpPWpGaD
Levocabastine—HRH1—GPCR ligand binding—PTCH1—skin cancer	0.000927	0.00366	CbGpPWpGaD
Levocabastine—HRH1—GPCR ligand binding—PTGER4—skin cancer	0.000903	0.00357	CbGpPWpGaD
Levocabastine—NTSR2—Signaling by GPCR—NRAS—skin cancer	0.000897	0.00354	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—BRAF—skin cancer	0.000843	0.00333	CbGpPWpGaD
Levocabastine—HRH1—GPCR downstream signaling—MC1R—skin cancer	0.000776	0.00306	CbGpPWpGaD
Levocabastine—NTSR2—Signaling by GPCR—KRAS—skin cancer	0.000772	0.00305	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—MC1R—skin cancer	0.000704	0.00278	CbGpPWpGaD
Levocabastine—NTSR2—Signaling by GPCR—HRAS—skin cancer	0.000656	0.00259	CbGpPWpGaD
Levocabastine—NTSR2—Signaling by GPCR—IL6—skin cancer	0.000628	0.00248	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—PTCH2—skin cancer	0.000576	0.00227	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—NRAS—skin cancer	0.00053	0.00209	CbGpPWpGaD
Levocabastine—HRH1—GPCR downstream signaling—PTGER4—skin cancer	0.00051	0.00201	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—SHH—skin cancer	0.000502	0.00198	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—PTCH1—skin cancer	0.000476	0.00188	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—SMO—skin cancer	0.000476	0.00188	CbGpPWpGaD
Levocabastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.00047	0.00186	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—PTGER4—skin cancer	0.000463	0.00183	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—KRAS—skin cancer	0.000456	0.0018	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—GLI2—skin cancer	0.000436	0.00172	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—MC1R—skin cancer	0.000416	0.00164	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—GLI1—skin cancer	0.00041	0.00162	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—TP53—skin cancer	0.000405	0.0016	CbGpPWpGaD
Levocabastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000405	0.0016	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—SUFU—skin cancer	0.000389	0.00154	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—HRAS—skin cancer	0.000388	0.00153	CbGpPWpGaD
Levocabastine—NTSR2—Signaling Pathways—IL6—skin cancer	0.000371	0.00147	CbGpPWpGaD
Levocabastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000344	0.00136	CbGpPWpGaD
Levocabastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000329	0.0013	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—SHH—skin cancer	0.000297	0.00117	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—RASA1—skin cancer	0.000295	0.00116	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—PTCH1—skin cancer	0.000281	0.00111	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—SMO—skin cancer	0.000281	0.00111	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—PTGER4—skin cancer	0.000274	0.00108	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—FOXO4—skin cancer	0.000242	0.000955	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—TERT—skin cancer	0.000161	0.000638	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—NRAS—skin cancer	0.000136	0.000537	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—BRAF—skin cancer	0.000128	0.000505	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—KRAS—skin cancer	0.000117	0.000462	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—HRAS—skin cancer	9.95e-05	0.000393	CbGpPWpGaD
Levocabastine—HRH1—Signaling by GPCR—IL6—skin cancer	9.52e-05	0.000376	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—NRAS—skin cancer	8.04e-05	0.000317	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—KRAS—skin cancer	6.92e-05	0.000273	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—TP53—skin cancer	6.15e-05	0.000243	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—HRAS—skin cancer	5.88e-05	0.000232	CbGpPWpGaD
Levocabastine—HRH1—Signaling Pathways—IL6—skin cancer	5.63e-05	0.000222	CbGpPWpGaD
